LES LABORATOIRES SERVIER

In News

Servier completes the acquisition of Day One Biopharmaceuticals - Servier

Servier - Apr 23, 2026

Insilico Medicine Announces US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology - Insilico Medicine

Insilico Medicine - Jan 04, 2026

Servier Buys Fragile X Syndrome Candidate for up to $450M - Genetic Engineering and Biotechnology News

Genetic Engineering and Biotechnology News - Sep 08, 2025

Cellectis (NASDAQ: CLLS) gets partial UCART19 V1 license termination ruling - Stock Titan

Stock Titan - Dec 15, 2025

Servier Acquires Day One Biopharmaceuticals for $2.5B, Betting on Tovorafenib and the Pediatric Glioma Frontier - Oncodaily

Oncodaily - Mar 12, 2026

France’s Servier Acquires Potential Fragile X Drug in $450 Million Deal - Bloomberg.com

Bloomberg.com - Sep 07, 2025

Insilico Medicine and Servier collaborate in cancer - BioWorld News

BioWorld News - Jan 05, 2026

White & Case wins “Impact Case of the Year” award at 2025 LMG Life Sciences EMEA Awards - White & Case LLP

White & Case LLP - Jun 12, 2025

Servier to acquire Day One, maker of pediatric cancer drug, for $2.5B - statnews.com

statnews.com - Mar 06, 2026

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide - PR Newswire

PR Newswire - Sep 02, 2025

Servier to widen rare cancer offerings with $2.5B buyout of Day One and glioma drug Ojemda - Fierce Pharma

Fierce Pharma - Mar 06, 2026

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio - Servier

Servier - Mar 06, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment